Does pregnancy affect the pharmacokinetics of efavirenz?

AIDS

Volumn 28, Issue 10, 2014, Pages 1542-1543

  Hill, Andrew ^a   Ford, Nathan ^b   Boffito, Marta ^c   Pozniak, Anton ^c   Cressey, Tim R ^d,e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

AREA UNDER THE CURVE; BLOOD SAMPLING; DRUG EFFICACY; GESTATIONAL AGE; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS LOAD; FEMALE; HIV INFECTIONS; PREGNANCY COMPLICATIONS, INFECTIOUS;

ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84902214959     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000279     Document Type: Letter

References (17)

1. World Health Organisation. Consolidated guidelines on antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. http://apps. who.int/iris/bitstream/10665/85321/1/ 9789241505727-eng. pdf [Accessed 2 January 2014].
2. World Health Organisation 2012. Technical update on treatment optimisation. Use of efavirenz during pregnancy. A public health perspective. June 2012. http://apps.who.int/iris/bitstream/10665/ 70920/1/9789241503792-eng. pdf [Accessed 2 January 2014].
3. US Food and Drug Administration. Efavirenz prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/020972s035, 021360s023lbl.pdf [Accessed 2 January 2014].
4. Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, et al. Safety of efavirenz in the first-trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28:S1.
5. Colbers A, Greupink R, Burger D. Pharmacological considerations on the use of antiretrovirals in pregnancy. Curr Opin Infect Dis 2013; 26:575-588.
6. Burger D, van der Helden I, la Porte C, van der Ende M, Groeneveld P, Richter C, et al. Interpatient variability in the pharmacokinetics of the HIV nonnucleoside reverse transciptase inhibitor efavirenz: the effect of gender, race and CYP2D6 polymorphism. Brit J Pharmacol 2006; 61:148-154.
7. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 2011; 66:2092-2098.
8. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15:71-75.
9. Gunda D, Kasang C, Kidenya B, Kabangila R, Mshana S, Kidola J, et al. EFV drug levels ref plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-Western Tanzania. PLoS One 2013; 8:75118.
10. Puls R, the ENCORE-1 study group. A daily dose of 400mg efavirenz (EFV) is noninferior to the standard 600mg dose: week 48 data from the ENCORE-1 study, a randomised, double-blind, placebo-controlled noninferiority trial [abstract WELBB01]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 2013; Kuala Lumpur, Malaysia.
11. Haas D, Hicks C, Seekins D, Cooper R, Gallant J, Carpenter C et al. A phase II, double blind, placebo controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (DMP-266) in combination with open-label zidovudine with lamivudine at 24 weeks (DMP 266-005) [abstract 698]. 5th Conference on Retroviruses and Opportunistic Infections; February 1998; Chicago.
12. Cressey T, Stek A, Capparelli E, Bowonwatanuowng C, Prommas S, Sirivatanapa P, et al., IMPAACT P1026s Team. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245-252.
13. McIlleron H, Martinson N, Denti P, Mashabela F, Hunt J, Shembe S et al., the TSHEPISO Study Team. Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral therapy (ART) with and without rifampin-containing tuberculosis (TB) treatment [Abstract no. MOAB0303]. 19th International AIDS Conference; July 2012; Washington DC.
14. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, et al. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol 2013; [Epub ahead of print].
15. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlbois E, Ruel T, et al. Hair and plasma data show that lopinavir,ritonavir and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acq Immune Defic Syndr 2013; 63:578-584.
16. Schneider S, Peltier A, Gras A, Arendt V, Karasi-Omes C, Mujawamariwa A, et al. Efavirenz in human breast milk, mothers and newborns plasma. J Aquir Immune Defic Syndr 2008; 48:450-454.
17. Cassard B, Roualt A, Damond F, Pattyn A, Batallan A, Legac S, et al. Plasma concentrations of efavirenz (EFV) in pregnant HIVinfected women treated with EFV containing regimen [Abstract no. WePe3.2C12]. 3rd IAS Conference on HIV Pathogenesis and Treatment; July 2005; Rio De Janeiro, Brazil.